london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Efficacy of intravitreal dexamethasone implant for the treatment of macular edema secondary to retinal vein occlusion

Poster Details

First Author: Z.Yazar TURKEY

Co Author(s):    H.H. Çağatay   G. Gökçe   Y. Koban   M. Ekinci   E.I. Durgunlu      0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate the efficacy of intravitreal dexamethasone implant (Ozurdex) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).


Kafkas University Faculty of Medicine, Department of Ophthalmology, Kars - TURKEY


Patients with branch retinal vein occlusion (n=18) and central retinal vein occlusion (n=12) were included in this prospective study. All patients received intravitreal injection of 0.7 mg dexamethasone intravitreal implant (Ozurdex ®) in operating rooms in sterile conditions, under topical anesthesia. Intravitreal implant was used as the first treatment. Best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) and complications were recorded before injection and fırst week, first month and then every month after injection. Findings were assessed statistically.


Of all the patients studied, 18 (60%) were male and 12 (40%) were female. The mean age was 65.87±8.9 (range 50 - 85) years; the mean follow-up time was 4.83±2.44 (range 3 to 10) months. The mean duration from symptoms to the initiation of the treatment was 12.83±6.4 (range 2 to 20) days. The mean BCVA was 1.15±0.57 logMAR at baseline,and at the final follow-up visit mean BCVA was improved to 0.73±0.57 logMAR (p=0.016). At baseline, the mean CRT was 536.46±148.66 µm, at the final follow-up visit the mean CRT improved to 319.71±96.5 µm (p=0.004). When compared with pre-injection, a meaningful improvement in visual acquity and a meaningful decrease in central macular thickness were observed after the injection. Average IOP was 16.15±6.09 mmHg before the injection, and it was 18.40±5.54 mmHg in the last check after the injection. After the injection, the mean IOP increase was 2.16 mmHg and it was not found meaningful statistically (p=0.31). Two patients (6.66%) were given anti glaucomatous treatment. Two patients (6.66%) required one more intravitreal dexamethasone implant injection in their 4th and 6th months follow up time.


In eyes with macular edema secondary to retinal vein occlusion, intravitreal injection of 0.7 mg dexamethasone intravitreal implant (Ozurdex ®), was found effective in the increase in visual acuity and decrease in macular edema. Patients should be carefully followed for recurrence of macular edema and potential IOP elevation.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy